Notwithstanding positive clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant opposition from pharmacy benefit managers. These companies are frequently creating limitations to coverage, including steep cost criteria and approval processes that restrict patient a